Ceylad: early results in two heavily pre-treated colorectal cancer patients promising
Ceylad said on Monday that it’s gotten promising early clinical results at the 3-month follow-up of the first dose-level in the solid tumor arm of the THINK trial (THerapeutic Immunotherapy with CAR-T NKR-2).